Mesenchymal stem/stromal cell-based cell-free therapy for the treatment of acute lung injury

J Cell Biochem. 2023 Sep;124(9):1241-1248. doi: 10.1002/jcb.30469. Epub 2023 Sep 5.

Abstract

Acute lung injury (ALI) is a severe medical condition that causes inflammation and fluid buildup in the lung, resulting in respiratory distress. Moreover, ALI often occurs as a complication of other medical conditions or injuries, including the coronavirus disease of 2019. Mesenchymal stem/stromal cells (MSCs) are being studied extensively for their therapeutic potential in various diseases, including ALI. The results of recent studies suggest that the beneficial effects of MSCs may not be primarily due to the replacement of damaged cells but rather the release of extracellular vesicles (EVs) and other soluble factors through a paracrine mechanism. Furthermore, EVs derived from MSCs preserve the therapeutic action of the parent MSCs and this approach avoids the safety issues associated with live cell therapy. Thus, MSC-based cell-free therapy may be the focus of future clinical treatments.

Keywords: ARDS; acute lung injury; cell-free strategies; extracellular vesicles; mesenchymal stem/stromal cells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury* / therapy
  • Cell- and Tissue-Based Therapy
  • Extracellular Vesicles*
  • Humans
  • Inflammation
  • Mesenchymal Stem Cells*